Volume 8, Issue 3, May 2020, Page: 51-54
The Effect of Paclitaxel on the Viability of U14 Cells
Gao Xuesong, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Lin Shaoqiang, The Hospital Management Department of Guangdong Pharmaceutical University, Guangzhou, China
Wang Xiaoyu, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Received: Apr. 18, 2020;       Accepted: Apr. 29, 2020;       Published: May 11, 2020
DOI: 10.11648/j.jgo.20200803.11      View  259      Downloads  71
The research is aimed to study the effect of paclitaxel on the viability of U14 cell line of cervical cancer, and to provide new ideas for further exploring the mechanism of paclitaxel chemotherapy to cervical cancer. Then, different concentrations of paclitaxel were used to treat U14 cells of cervical cancer in logarithmic phase growth. After culturing these cells for 24h, 48h or 72h, MTT method and automatic enzyme-linked immunosorbent assay system were used to evaluate the survival rate of cultured cells with different concentrations of paclitaxel. These results showed that paclitaxel has a significant inhibitory effect on the proliferation of U14 cells in a concentration- and time-dependent manner, compared with the control group. Paclitaxel concentration of the IC50 of U14 cells was 168.8μg/ml at 24h, 22. 15 μg/ml at 48h and 8. 04μg/ml at 72 h. As the time increased, the IC50 value of U14 cells gradually decreased. The results of linear regression analysis are as follows: 24 h, y=-0.005x + 1.344, R2=0.779; 48 h, y=-0.013x +0.788, R2=0.923; 72 h, y=-0.056x + 0.950, R2=0.908. The dose-effect curve of paclitaxel on U14 cells for 48 h and the trend of linear regression fitting are better, and the growth inhibition of cells shows a clear relationship between time and dose. In conclusion, paclitaxel has an obvious inhibitory effect on the activity of cervical cancer U14 cells in mice, which provides new ideas for further exploring the mechanism of cervical cancer paclitaxel chemotherapy.
Paclitaxel, Cervical Cancer, Cell Viability, U14 Cell
To cite this article
Gao Xuesong, Lin Shaoqiang, Wang Xiaoyu, The Effect of Paclitaxel on the Viability of U14 Cells, Journal of Gynecology and Obstetrics. Vol. 8, No. 3, 2020, pp. 51-54. doi: 10.11648/j.jgo.20200803.11
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Small W, Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer 2017, 123 (13): 2404-2412.
Song B, Ding C, Chen W, Sun H, Zhang M, Chen W. Incidence and mortality of cervical cancer in China, 2013. Chinese journal of cancer research 2017, 29 (6): 471-476.
Yang K, Park W, Huh SJ, Bae DS, Kim BG, Lee JW. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiation oncology journal 2017, 35 (1): 39-47.
Lee SY, Lee NR, Cho DH, Kim JS. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncology letters 2017, 14 (1): 73-78.
Wall ME. Camptothecin and paclitaxel: discovery to clinic. Medicinal research reviews 1998, 18 (5): 299-314.
Naaz F, Haider MR, Shafi S, Yar MS. Anti-tubulin agents of natural origin: Targeting paclitaxel, vinca, and colchicine binding domains. European journal of medicinal chemistry 2019, 171: 310-331.
Chavez JD, Keller A, Zhou B, Tian R, Bruce JE. Cellular Interactome Dynamics during Paclitaxel Treatment. Cell reports 2019, 29 (8): 2371-2383 e2375.
Wang H, Zhu Y, Hao C, Fan J, Liu Y, Wang Y. Establishment of a drug-resistant human cervical cancer cell line and research on its drug-resistance. Journal of cancer research and therapeutics 2019, 15 (6): 1221-1225.
Lee BE, Choi BY, Hong DK, Kim JH, Lee SH, Kho AR, Kim H, Choi HC, Suh SW. The cancer chemotherapeutic agent paclitaxel (Paclitaxel) reduces hippocampal neurogenesis via down-regulation of vesicular zinc. Scientific reports 2017, 7 (1): 11667.
Aborehab NM, Osama N. Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells. Cancer cell international 2019, 19: 154.
Zheng FY, Wang SG, Hou WX, Xiao YC, Liu PC, Shi XY, Shen MW. Comparative study of resazurin reduction and MTT assays for cytocompatibility evaluation of nanofibrous materials. Anal Methods-Uk 2019, 11 (4): 483-489.
Lee KH, Yim EK, Kim CJ, Namkoong SE, Um SJ, Park JS. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecologic oncology 2005, 98 (1): 45-53.
Mao BD, Xu P, Xu P, Zhong Y, Ding WW, Meng QZ. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. Journal of biosciences 2019, 44 (2).
Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cellular & molecular biology letters 2019, 24: 40.
Bava SV, Puliyappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of paclitaxel-induced apoptosis by curcumin involves down-regulation of nuclear factor- B and the serine/threonine kinase Akt and is independent of tubulin polymerization (vol 280, pg 6301, 2005). Journal of biological chemistry 2018, 293 (31): 12283-12283.
Browse journals by subject